[Antibodies to lipoid A in the treatment of XXXX ].

@entity1 @entity295 @entity326 @entity5856 @entity281
The protective effect of high-titer anti-lipid A hyperimmune globulin with respect to the course of the disease and the mortality rate was studied in @entity1 with @entity295 verified by positive blood cultures. Six @entity1 were treated with anti-lipid A in an open study. Dramatic improvement in fever curves and clinical condition in some of the @entity1 encouraged us to start a randomized double blind study. So far, 17 @entity1 have entered the study, 16 of whom were evaluable. Immediately after a positive blood culture was found, @entity1 received either high doses of anti-lipid A or placebo (saline solution) on two subsequent days. Before and after each infusion blood samples were taken in order to assess serum bactericidal activity and anti-lipid A titers. Because of the still small numbers of @entity1 the results of both studies were summarized. In all @entity1 treated with anti-lipid A clear-cut increases in anti-lipid A titers were shown. @entity1 with repeated gram-negative @entity281 showed higher median anti-lipid A titers than @entity1 without such a history. The @entity1 treated with anti-lipid A immune globulin @entity5856 a significantly milder course than the placebo group. The severe signs of @entity326 were reversed in seven of 15 patients on anti-lipid A compared to two of seven @entity1 treated with placebo. In the anti-lipid A-treated group, three of 15 @entity1 died, and in the placebo group two of seven. This difference is not statistically significant.
